🎉Exciting times for NRx Pharmaceuticals! They're making strides in the development of NRX-101, a breakthrough therapy for suicidal bipolar depression & chronic pain.👩‍🔬💊

They've recently announced plans to submit a New Drug Application for NRX-100, a ketamine-based treatment for suicidal depression.📝💡

They're also working on a proprietary formulation of IV Ketamine, HTX-100. This new formulation has a neutral pH, unlike the acidic pH of generic ketamine, making it a game-changer.🧪🔬

NRXP announced successful results of its clinical trial of NRX-101 vs. lurasidone in the treatment of suicidal bipolar depression. With positive data, NRXP is now eligible to receive an additional $4 million from partners Alvogen, Inc. and Lotus Pharmaceuticals, Inc.💰📈

They're also tackling chronic pain with D-cycloserine, the active ingredient in NRX-101. It reduces chronic pain to levels previously associated with oral opioid drugs but without the addiction and side effects.👏🙌

NRXP has also established HOPE Therapeutics to develop and launch IV Ketamine. They're planning to spin it out as a separate company, with term sheets received from prospective anchor investors for $60 million of new investment.💼🚀

NRXP delivered a 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. They've added over $8 million in working capital.📊💪

They're planning to distribute shares of HOPE Therapeutics and royalty rights on Ketamine sales to existing NRx shareholders.🎁🎊

Stay tuned for more updates on NRXP's journey! 🌟🚀